KRYS צמיחת רווח למניה השנה Krystal Biotech, Inc.

The annual earnings per share trajectory demonstrates revenue dynamics, where 12.00 captures the current value of the indicator. Krystal Biotech, Inc. (KRYS) possesses a unique gene therapy platform that ensures pricing power through its drug Vyjuvek. The explosive commercial success of the skin-correcting genetic gel is complemented by strategic partnerships with leading global clinics and research centers.
פילוחים אנליטיים ודוחות נתונים של חברת Krystal Biotech Inc (KRYS)

Positive earnings per share dynamics signal to institutional investors the high efficiency of Krystal Biotech, Inc. (KRYS) organic scaling following the commercialization of its core drug. By analyzing the EPS YoY percentage shift on GURU.Markets, you assess the real return on capital accounting for operational logistics costs, which confirms the fundamental resilience of the business in the absence of external mergers.